MICHELLE CHIN: Open Payments
NPI 1649645938 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,115 in 61 payments from 13 companies in 2025. Trend: 2023 $889 · 2024 $970 · 2025 $2,115
Food & beverage: $2,115
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $505 |
| Otsuka America Pharmaceutical, Inc. | 9 | $358 |
| Neurocrine BioSciences, Inc. | 4 | $307 |
| Vanda Pharmaceuticals Inc. | 9 | $237 |
| E.R. Squibb & Sons, L.L.C. | 3 | $167 |
| Janssen Pharmaceuticals, Inc | 2 | $147 |
| Teva Pharmaceuticals USA, Inc. | 2 | $136 |
| Axsome Therapeutics, Inc. | 4 | $71 |
| Alkermes, Inc. | 4 | $67 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $54 |
Products named: VRAYLAR, INGREZZA, FANAPT, REXULTI, COBENFY, INVEGA SUSTENNA, AUSTEDO XR, ABILIFY MAINTENA.
Industry payments across ID — which companies pay providers there.
